**Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study**

**T. Peto1 | T. Akerele2 | A. Sagkriotis3 | S. Zappacosta4 | A. Clemens3,5 | U. Chakravarthy1**

1Centre for Public Health, Queen's University Belfast, Belfast, UK

2Hinchingbrooke Hospital, Huntingdon, UK

3Novartis Pharma AG, Basel, Switzerland

4IQVIA Real World Insights, Basel, Switzerland

5Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany

# Supplementary material

# TABLE S1 Baseline demographics and characteristics of patients with DME, grouped by unilateral or bilateral treatment

|  |  |  |  |
| --- | --- | --- | --- |
| **Demographic or characteristic** | **Unilateral treatment (first eye)**  **(N = 655)** | **Unilateral to bilateral treatment**  **(first eye)**  **(N = 45)** | **Bilateral treatment at index date**  **(N = 155)** |
| Age, mean (SD) | 67.5 (12.8) | 67.8 (12.1) | 63.8 (13.0) |
| Men, *n* (%) | 385 (58.8) | 32 (71.1) | 96 (61.9) |
| VA, mean (SD), *n* (%) |  |  |  |
| n | 601 | 41 | 254 |
| Patients with <33 ETDRS letters | 36 (6.0) | 1 (2.4) | 20 (7.9) |
| Patients with 33–73 ETDRS letters | 400 (66.6) | 28 (68.3) | 170 (66.9) |
| Patients with >73 ETDRS letters | 165 (27.5) | 12 (29.3) | 64 (25.2) |

*Note:* All patients had ≥12 months’ follow-up.

Abbreviations: DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation; VA, visual acuity.

# TABLE S2 Duration of injection intervals during the second year of treatment with anti-VEGF agents

|  |  |
| --- | --- |
| **Interval length** | **Patient eyes with DME treated with anti-VEGF agents**  **(n = 476)** |
| ≥1 injection interval, *n* (%) |  |
| <4 weeks | 0 (0.0) |
| 4–<8 weeks | 24 (5.1) |
| 8–<12 weeks | 104 (21.8) |
| ≥12 weeks\* | 348 (73.1) |
| ≥16 weeks\* | 180 (37.9) |
| ≥20 weeks\* | 85 (17.9) |
| ≥2 consecutive injection intervals, *n* (%) |  |
| <4 weeks | 0 (0.0) |
| 4–<8 weeks | 150 (31.5) |
| 8–<12 weeks | 69 (14.5) |
| ≥12 weeks | 155 (32.6) |
| ≥16 weeks\* | 24 (5.0) |
| ≥20 weeks\* | 6 (1.3) |


\*Categories not mutually exclusive.  
Abbreviations: DME, diabetic macular edema; VEGF, vascular endothelial growth factor.

# TABLE S3 Number of anti-VEGF injections and clinic visits in patients with DME, grouped by unilateral or bilateral treatment

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Unilateral treatment (first eye)**  **(*N* = 655)** | **Unilateral to bilateral treatment**  **(first eye)**  **(*N* = 45)** | **Bilateral treatment at index**  **(*N* = 155)** |
| **Months 0–3** |  |  |  |
| Number of injection visits |  |  |  |
| Total number of injections | 2061 | 134 | 844 |
| Number of injections per patient eye, mean (SD) | 3.1 (0.6) | 3.0 (0.7) | 3.1 (0.7) |
| Number of injection-free visits |  |  |  |
| Total number of injection-free visits | 569 | 18 | 426 |
| Number of injection-free visits per patient eye, mean (SD) | 0.9 (1.2) | 0.4 (0.6) | 1.6 (1.5) |
| Number of total visits |  |  |  |
| Total number of visits | 2630 | 152 | 1270 |
| Number of total visits per patient eye, mean (SD) | 4.0 (1.4) | 3.4 (1) | 4.7 (1.7) |
| **Months 3–12** |  |  |  |
| Number of injection visits |  |  |  |
| Total number of injections | 2938 | 201 | 1255 |
| Number of injections per patient eye, mean (SD) | 4.5 (1.7) | 4.5 (1.8) | 4.6 (1.7) |
| Number of injection-free visits |  |  |  |
| Total number of injection-free visits | 3410 | 213 | 1660 |
| Number of injection-free visits per patient eye, mean (SD) | 5.2 (3.6) | 4.7 (2.7) | 6.1 (5.2) |
| Number of total visits |  |  |  |
| Total number of visits | 6348 | 414 | 2915 |
| Number of total visits per patient eye, mean (SD) | 9.7 (4.2) | 9.2 (3) | 10.7 (5.9) |

*Note:* All patients had ≥12 months’ follow-up.

Abbreviations: DME, diabetic macular edema; SD, standard deviation; VEGF, vascular endothelial growth factor.

****

# FIGURE S1 Change from baseline in VA over 2 years of treatment with anti-VEGF agents.

Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; VEGF, vascular endothelial growth factor.